SR 2566

Drug Profile

SR 2566

Latest Information Update: 09 Nov 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LEO Pharma
  • Class Anti-inflammatories; Benzoic acids
  • Mechanism of Action Arachidonic acid inhibitors; Leukotriene B4 receptor antagonists; Leukotriene D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation; Skin disorders

Most Recent Events

  • 09 Nov 2000 Discontinued-Preclinical for Inflammation in Denmark (Topical)
  • 09 Nov 2000 Discontinued-Preclinical for Skin disorders in Denmark (Topical)
  • 07 Sep 1998 No-Development-Reported for Inflammation in Denmark (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top